These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36342143)

  • 1. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension.
    Freeman MW; Halvorsen YD; Marshall W; Pater M; Isaacsohn J; Pearce C; Murphy B; Alp N; Srivastava A; Bhatt DL; Brown MJ;
    N Engl J Med; 2023 Feb; 388(5):395-405. PubMed ID: 36342143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Hypertens Res; 2023 Jan; 46(1):108-118. PubMed ID: 36266539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial.
    Laffin LJ; Rodman D; Luther JM; Vaidya A; Weir MR; Rajicic N; Slingsby BT; Nissen SE;
    JAMA; 2023 Sep; 330(12):1140-1150. PubMed ID: 37690061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.
    Williams B; MacDonald TM; Morant SV; Webb DJ; Sever P; McInnes GT; Ford I; Cruickshank JK; Caulfield MJ; Padmanabhan S; Mackenzie IS; Salsbury J; Brown MJ;
    Lancet Diabetes Endocrinol; 2018 Jun; 6(6):464-475. PubMed ID: 29655877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
    Schlaich MP; Bellet M; Weber MA; Danaietash P; Bakris GL; Flack JM; Dreier RF; Sassi-Sayadi M; Haskell LP; Narkiewicz K; Wang JG;
    Lancet; 2022 Dec; 400(10367):1927-1937. PubMed ID: 36356632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension.
    Forzano I; Mone P; Varzideh F; Jankauskas SS; Kansakar U; De Luca A; Santulli G
    Front Endocrinol (Lausanne); 2022; 13():1097968. PubMed ID: 36568122
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
    Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
    Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension.
    Dey S; Frishman WH; Aronow WS
    Cardiol Rev; 2023 Aug; ():. PubMed ID: 37548462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
    McGill JB; Reilly PA
    Clin Ther; 2001 Jun; 23(6):833-50. PubMed ID: 11440284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
    Pool JL; Glazer R; Chiang YT; Gatlin M
    J Hum Hypertens; 1999 Apr; 13(4):275-81. PubMed ID: 10333347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects.
    Freeman MW; Bond M; Murphy B; Hui J; Isaacsohn J
    Am J Cardiovasc Drugs; 2023 May; 23(3):277-286. PubMed ID: 36790596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial.
    Peters R; Beckett N; Forette F; Tuomilehto J; Clarke R; Ritchie C; Waldman A; Walton I; Poulter R; Ma S; Comsa M; Burch L; Fletcher A; Bulpitt C;
    Lancet Neurol; 2008 Aug; 7(8):683-9. PubMed ID: 18614402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone synthase inhibition in humans.
    Azizi M; Amar L; Menard J
    Nephrol Dial Transplant; 2013 Jan; 28(1):36-43. PubMed ID: 23045428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.